Cancer diagnosis traditionally depends on tissue biopsy-surgical or needle-based procedures used to extract samples directly from tumor sites. While these gold standards remain, a transformative innovation is rapidly acquiring land in oncology: liquid biopsy.

Liquid biopsy is a minimum invasive method that detects tumor-rich materials in body fluids, most blood. Dr. According to Mandeep Singh Malhotra, this approach eliminates the need for surgical processes, which depends on a simple blood draw to catch the data related to significant cancer.

These tests analyze tumors DNA (CTDNA), circulating tumor cells (CTCs), and other biomarkers that transmit circulars. This information can help in detecting the presence of cancer, track its progression and assess the reaction of treatment – without all discomfort and risks associated with traditional biopsy.

Dr. According to Malhotra, liquid biopsy can be detected:

CTDNA and CTCs: These sheds by tumor cells provide insight into tumor characteristics and mutation.

CFDNA (SAIL-Free DNA): It contains both normal and tumors pieces of DNA, which help identify genetic uplains such as BRCA1/2 and TP53 that suggest a prediction for cancer.

Immune System Change: A novel approach under the development track changes in white blood cells (WBCs), which reflects the response of the immune system for the formation of early tumors – to potentially identify cancer before the clinical symptoms emerge.

Medical oncologist Dr., Advisor to Shalby Hospital SG. Aishwariya Raj has described liquid biopsy as a “revolutionary advancement” for its simplicity, safety and ability to offer real -time data.

1. Monitoring and monitoring liquid biopsy allows for frequent testing, which helps doctors:

• Monitor subsequent treatment of patients.

• First predict the recurrence of cancer compared to traditional imaging methods such as PET scans.

• Adjust the remedies quickly in response to the development of the tumor.

2. Precision

By providing DNA/RNA data, Dr. Malhotra says, liquid biopsy supports targeted cancer treatment. Oncologists can study genomic makeup of tumors and determine drugs or neutrasuticals that are specifically designed to combat cancer -running genetic abstinence.

3. Initial identification and special screening

Although current is not recommended for mass screening, the liquid biopsy shows the promise in select landscapes:

• Unclear uterine mass: When traditional biopsy is aggressive, liquid biopsy may guide further diagnosis.
• Oral lesions in high -risk individuals: Blood tests may benefit from smoking or tobacco chewing mouth lesions to determine the risk of cancer.
• Hard-to-byopsy sites: In cases associated with wounds in lungs, liver, or bones-where surgical biopsy is risky-tilal biopsy is a viable option.
• Biopsy hesitating: Some patients avoid biopsy for fear of complications or spread of disease. Liquid biopsy provides a safe, non-invasive solution.

Promising, there are boundaries of liquid biopsy. For example, it is not suitable for diagnosing brain tumors, as the blood-brain barrier prevents tumor cells or DNA from reaching the bloodstream.

With the ongoing research with refining its sensitivity and scope, liquid biopsy is designed to change cancer diagnosis and treatment landscape. “This is ideal for early identity and real -time monitoring,” Dr. “And especially beneficial for high risk or passive patients,” says Raj.

As the field of individual medicine develops, liquid biopsy can become an indispensable tool – safe, sharp, and more accurate insight for cancer care.

Now get the latest news with health and braking news and top headlines worldwide.